Clinical Commander

Back to dossier
neonatal.respiratory-distress-syndrome.v1PRODUCTION
neonatal.respiratory-distress-syndrome.v1

Neonatal Respiratory Distress Syndrome (RDS)

pediatricsacuteneonatalpediatric
Hard-required inputs
0 / 13
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Frame by gestational age cohort (extreme <28 wk vs very 28-32 wk vs late preterm 32-34 vs term ≥37) and postnatal age; antenatal corticosteroid status; presenting work of breathing.

Inputs
3
Actions
0
Advance rule
Set
Advance when

GA cohort + ACS status + birthweight captured

Patient inputs (15)

Adequate ACS course (betamethasone or dexamethasone × 24 h before delivery) reduces RDS severity / mortality; out-of-engine maternal pathway

Maternal diabetes increases RDS risk (delayed lung maturation); chorioamnionitis is mixed effect

Tachypnea + grunting = classical signs; sustained RR >70 → escalate

Target 90-94% per Sweet 2022 (no longer 85-89% per SUPPORT post-hoc); FiO₂ requirement drives surfactant decision

Silverman-Andersen score (or clinical equivalent) for severity grading

RDS incidence falls steeply with GA; <28 wks ~80%, 28-32 ~40%, 32-34 ~10%, >34 <5%; drives surfactant + ventilation strategy

Per-kg dosing for surfactant (200 mg/kg poractant alfa) and caffeine (20 mg/kg load)

RDS presents within hours of life; surfactant ideally < 2 h; caffeine within 72 h of life (Sweet 2022)

pH, pCO₂, pO₂ drive ventilation strategy; rising pCO₂ + falling pH → escalate

WBC + I:T ratio screens for sepsis coinfection (route to neonatal.early-onset-sepsis.v1)

Hypoglycemia is common comorbid; cross-reference neonatal.hypoglycemia.v1

Ground-glass + air bronchograms = RDS; alternative patterns (pneumothorax, MAS, pneumonia, CDH) drive different pathways

Thermoregulation in delivery room is essential; cold stress worsens surfactant function

Echo if pre-/post-ductal SpO₂ gradient or persistent hypoxemia → route to neonatal.persistent-pulmonary-hypertension.v1

Sepsis coinfection rule-out; empiric ampicillin + gentamicin if CXR / clinical ambiguous

* = hard-required. Engine cannot meaningfully run until these are filled.

No severity triggers declared for this engine.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENToptionalDrives dose adjustment
Loading…

Recommended regimen

Neonatal RDS — surfactant (LISA / INSURE) + caffeine for AOP / extubation support (Sweet 2022 PMID 36863329; SUPPORT NEJM 2010 PMID 20472939; Schmidt CAP NEJM 2007 PMID 17989382)
axis: rds_respiratory_pharmacotherapy
Selected axis "Neonatal RDS — surfactant (LISA / INSURE) + caffeine for AOP / extubation support (Sweet 2022 PMID 36863329; SUPPORT NEJM 2010 PMID 20472939; Schmidt CAP NEJM 2007 PMID 17989382)" by default fallback (first axis)
  • poractant alfa
    first line
    pulmonary_surfactant_porcine
    poractant alfa 200 mg/kg intratracheal via LISA (preferred) or INSURE (preterm <34 wks PMA, FiO₂ > 30% on CPAP, within first 2 h of life ideally) • intratracheal_LISA_or_INSURE • single dose; may repeat 100 mg/kg at 6-12 h if persistent need (FiO₂ > 40%) (max: max 2 doses (200 mg/kg initial + 100 mg/kg redose); rare third dose only for severe ongoing need)
    triggers: rds_preterm_with_fio2_above_30pct_on_cpap, preterm_intubated_with_rds_pattern_cxr
    Sweet 2022 GRADE strong recommendation for LISA delivery (PMID 36863329); SUPPORT 2010 demonstrated CPAP non-inferiority to early surfactant but rescue dosing improves outcomes (Neofax 2024; Cochrane animal-derived surfactant)
    rxcui 236381
  • beractant
    second line
    pulmonary_surfactant_bovine
    beractant 100 mg/kg (4 mL/kg) intratracheal in 4 aliquots with position changes • intratracheal_endotracheal_tube • single dose; may repeat q6h up to 4 total doses for ongoing need (max: max 4 doses (400 mg/kg cumulative))
    triggers: rds_preterm_alternative_to_poractant_alfa, institutional_formulary_choice
    Bovine surfactant alternative; longer administration time + larger volume per dose vs poractant alfa; Neofax 2024 + Sweet 2022 conditional recommendation
    rxcui 46967
  • caffeine citrate
    first line
    methylxanthine_CNS_stimulant
    caffeine citrate 20 mg/kg IV or PO load (=10 mg/kg caffeine base) over 30 min, then 5-10 mg/kg/day maintenance starting 24 h after load • IV or PO • load once, then maintenance daily (max: max maintenance 10 mg/kg/day caffeine citrate (=5 mg/kg/day caffeine base))
    triggers: preterm_lt_32_wks_for_aop_prophylaxis, extubation_attempt_with_aop_risk
    CAP trial (Schmidt NEJM 2007 PMID 17989382) — caffeine for AOP improved survival without neurodev disability at 18-21 mo; Sweet 2022 strong recommendation for early caffeine in preterm <30 wks; safer therapeutic window than theophylline (Neofax 2024)
    rxcui 20033

ed playbook — drug actions (2)

  1. 1. CPAP 5-6 cm H₂O if breathing
    CPAP 5-6 cm H₂O • nasal_or_mask • continuous
    trigger: Preterm breathing with respiratory distress
    Sweet 2022 strong recommendation; SUPPORT NEJM 2010 PMID 20472939
  2. 2. poractant alfa 200 mg/kg via LISA or INSURE
    rxcui 236381
    200 mg/kg • intratracheal • single dose
    trigger: FiO₂ > 30% on CPAP or intubated for respiratory failure
    Sweet 2022 + Neofax 2024

Auto-drafted A&P note

ed

Subjective

- Possible entry pathways: Preterm neonate with tachypnea, grunting, retractions, nasal flaring within first hours of life (Sweet 2022 PMID 36863329); Preterm with rising FiO₂ requirement to maintain SpO₂ 90-94% — surfactant escalation trigger (Sweet 2022); CXR with diffuse ground-glass / reticulogranular pattern + air bronchograms — classical RDS finding.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Neonatal Respiratory Distress Syndrome (RDS)** (neonatal.respiratory-distress-syndrome.v1).
Phenotype framing: RDS vs transient tachypnea of newborn (TTN — typically term / late-preterm post-C-section, resolves in 24-48 h). RDS vs meconium aspiration (MAS — meconium-stained fluid, typical term/post-term, asymmetric CXR). RDS vs neonatal pneumonia / sepsis (overlapping features; CXR may show focal infiltrate). RDS vs CDH (scaphoid abdomen, mediastinal shift on CXR). RDS vs CHD (cyanotic; differential cyanosis with pre-/post-ductal SpO₂ gradient).
Scope: Frame by gestational age cohort (extreme <28 wk vs very 28-32 wk vs late preterm 32-34 vs term ≥37) and postnatal age; antenatal corticosteroid status; presenting work of breathing.

Plan

Regimen axis: **Neonatal RDS — surfactant (LISA / INSURE) + caffeine for AOP / extubation support (Sweet 2022 PMID 36863329; SUPPORT NEJM 2010 PMID 20472939; Schmidt CAP NEJM 2007 PMID 17989382)**.
1. poractant alfa poractant alfa 200 mg/kg intratracheal via LISA (preferred) or INSURE (preterm <34 wks PMA, FiO₂ > 30% on CPAP, within first 2 h of life ideally) intratracheal_LISA_or_INSURE single dose; may repeat 100 mg/kg at 6-12 h if persistent need (FiO₂ > 40%) (pulmonary_surfactant_porcine, first line) — Sweet 2022 GRADE strong recommendation for LISA delivery (PMID 36863329); SUPPORT 2010 demonstrated CPAP non-inferiority to early surfactant but rescue dosing improves outcomes (Neofax 2024; Cochrane animal-derived surfactant)
2. beractant beractant 100 mg/kg (4 mL/kg) intratracheal in 4 aliquots with position changes intratracheal_endotracheal_tube single dose; may repeat q6h up to 4 total doses for ongoing need (pulmonary_surfactant_bovine, second line) — Bovine surfactant alternative; longer administration time + larger volume per dose vs poractant alfa; Neofax 2024 + Sweet 2022 conditional recommendation
3. caffeine citrate caffeine citrate 20 mg/kg IV or PO load (=10 mg/kg caffeine base) over 30 min, then 5-10 mg/kg/day maintenance starting 24 h after load IV or PO load once, then maintenance daily (methylxanthine_CNS_stimulant, first line) — CAP trial (Schmidt NEJM 2007 PMID 17989382) — caffeine for AOP improved survival without neurodev disability at 18-21 mo; Sweet 2022 strong recommendation for early caffeine in preterm <30 wks; safer therapeutic window than theophylline (Neofax 2024)

Setting playbook (ed) — Delivery-room (or outside-NICU) resuscitation — thermoregulation + CPAP-first if breathing + intubation + surfactant if FiO₂ > 30% or apneic; transfer to NICU (icu vocabulary).
4. CPAP 5-6 cm H₂O if breathing CPAP 5-6 cm H₂O nasal_or_mask continuous — Preterm breathing with respiratory distress (Sweet 2022 strong recommendation; SUPPORT NEJM 2010 PMID 20472939)
5. poractant alfa 200 mg/kg via LISA or INSURE 200 mg/kg intratracheal single dose — FiO₂ > 30% on CPAP or intubated for respiratory failure (Sweet 2022 + Neofax 2024)

Non-pharmacologic actions:
- Plastic wrap if <32 wks gestation for thermoregulation
- Radiant warmer at delivery; transport in pre-warmed isolette
- Delayed cord clamping ≥ 60 s per Sweet 2022 if no resuscitation needed at birth
- Bag-mask ventilation if HR <100 despite CPAP
- Intubation if persistent apnea / HR <100 despite PPV

AVOID / contraindication checks:
- Surfactant administer with experienced team only airway skill required (Sweet 2022)
- LISA requires spontaneous breathing not suitable if apneic (Sweet 2022)
- Caffeine tachycardia and feeding intolerance monitor (Neofax 2024)
- Permissive hypercapnia pco2 50 to 65 acceptable to minimize VILI (Sweet 2022)
- SpO2 target 90 to 94 percent not lower per SUPPORT post hoc (Sweet 2022)

Monitoring

Regimen monitoring:
- Continuous SpO₂ + ETCO₂ if intubated
- ABG / CBG before and after surfactant
- CXR within 1 h of admission; PRN if deterioration
- Daily weight + growth + nutrition
- Caffeine: HR + feeding tolerance; therapeutic level not routinely needed unless breakthrough apnea
- BPD assessment at 28 d + 36 wk PMA
- ROP screening per ophthalmology schedule
- Hearing screen (AABR) pre-discharge

Setting (ed) monitoring:
- Pre-ductal SpO₂
- HR continuous
- Temperature continuous

Follow-up plan: High-risk follow-up clinic at 3 + 6 + 12 + 24 mo (Bayley III at 18-24 mo). ROP follow-up per ophthalmology. Hearing surveillance. RSV prophylaxis with nirsevimab or palivizumab per AAP / ACIP. Immunization catch-up per ACIP. Lactation continued.
- Close-out criterion: Outpatient follow-up scheduled; family education complete

Monitoring phase: Continuous SpO₂ + cardiorespiratory + ETCO₂ if intubated. Serial ABG. Daily CXR if intubated; PRN if CPAP. Surfactant-redose at 6-12 h if persistent need (FiO₂ > 40%). Caffeine level if breakthrough apnea on therapeutic dose. Weight + growth + nutrition daily. BPD risk monitoring at 28 d + 36 wk PMA. Pre-discharge: hearing screen (AABR), eye exam (ROP screen), neurodevelopmental baseline.

Disposition

Current setting: ed — Delivery-room (or outside-NICU) resuscitation — thermoregulation + CPAP-first if breathing + intubation + surfactant if FiO₂ > 30% or apneic; transfer to NICU (icu vocabulary).

Disposition criteria:
- Transfer to NICU (icu) once initial stabilization + surfactant given

Escalation triggers (move to higher acuity):
- Persistent HR < 60 despite ventilation → chest compressions + NICU code
- Pneumothorax (asymmetric breath sounds, sudden deterioration) → needle decompression
- Surfactant administration → transfer to NICU under continuous monitoring

Earlier-Return Triggers

- No severity triggers declared for this engine.

Citations

- Sweet DG et al — European Consensus Guidelines on Management of RDS: 2022 Update (Neonatology 2023 PMID 36863329); SUPPORT NEJM 2010 (PMID 20472939) for early-CPAP vs early-surfactant equivalence; Schmidt CAP NEJM 2007 (PMID 17989382) for caffeine long-term outcomes. [PMID:36863329](https://pubmed.ncbi.nlm.nih.gov/36863329/)
- Cited evidence (PMID 20472939) [PMID:20472939](https://pubmed.ncbi.nlm.nih.gov/20472939/)
- Cited evidence (PMID 17989382) [PMID:17989382](https://pubmed.ncbi.nlm.nih.gov/17989382/)

Last reconciled with current guidelines: 2026-05-26.
References
  • Sweet DG et al — European Consensus Guidelines on Management of RDS: 2022 Update (Neonatology 2023 PMID 36863329); SUPPORT NEJM 2010 (PMID 20472939) for early-CPAP vs early-surfactant equivalence; Schmidt CAP NEJM 2007 (PMID 17989382) for caffeine long-term outcomes. — PMID:36863329
  • Cited evidence (PMID 20472939) — PMID:20472939
  • Cited evidence (PMID 17989382) — PMID:17989382